SECOND AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • January 13th, 2014 • Intrexon Corp • Services-commercial physical & biological research
Contract Type FiledJanuary 13th, 2014 Company IndustryTHIS SECOND AMENDMENT is entered into as of this 10th day of January, 2014 and serves to amend the Exclusive Channel Collaboration Agreement entered into by and between Intrexon Corporation (“Intrexon”) and Fibrocell Science, Inc. (“Fibrocell”), on October 5, 2012 and first amended on June 28, 2013 (as amended, the “Agreement”). All capitalized terms not defined herein shall have the meaning set forth in the Agreement.
20374 Seneca Meadows Pkwy Germantown, MD 20876 precigen.com February 19, 2020 Fibrocell Science, Inc. c/o Castle Creek Biosciences, Inc.Channel Collaboration Agreement • July 16th, 2021 • Castle Creek Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledJuly 16th, 2021 Company Industry
Exclusive Channel Collaboration AgreementChannel Collaboration Agreement • April 15th, 2014 • AmpliPhi Biosciences Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledApril 15th, 2014 Company Industry JurisdictionThis Exclusive Channel Collaboration Agreement (the “Agreement”) is made and entered into effective as of March 29, 2013 (the “Effective Date”) by and between Intrexon Corporation, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and Ampliphi Biosciences Corporation, a Washington corporation having a place of business at 800 E. Leigh St., Suite 54, Richmond, VA, 23219 (“Ampliphi”). Intrexon and Ampliphi may be referred to herein individually as a “Party”, and collectively as the “Parties.”
AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • May 11th, 2017 • Oragenics Inc • Pharmaceutical preparations
Contract Type FiledMay 11th, 2017 Company IndustryThis AMENDMENT TO EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Amendment”) is effective as of May 10, 2017 (the “Amendment Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), INTREXON ACTOBIOTICS NV, a naamloze vennootschap under Belgian law with registered offices at Technologiepark 4, 9052 Zwijnaarde (CBE no. 0882.251.820 (Ghent), Belgium (“Actobiotics”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, U.S.A. (“Oragenics”). Intrexon and Actobiotics together on the one hand and Oragenics on the other hand may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • January 4th, 2016 • Fibrocell Science, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 4th, 2016 Company Industry JurisdictionTHIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of December 31, 2015 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and FIBROCELL SCIENCE, INC., a Delaware corporation having its principal place of business at 405 Eagleview Boulevard, Exton, PA 19341 (“Fibrocell”). Intrexon and Fibrocell may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • June 11th, 2012 • Oragenics Inc • Pharmaceutical preparations • New York
Contract Type FiledJune 11th, 2012 Company Industry JurisdictionTHIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of June 5, 2012 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and ORAGENICS, INC., a Florida corporation having its principal place of business at 3000 Bayport Drive, Suite 685, Tampa, FL 33607 (“Oragenics”). Intrexon and Oragenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”
EX-10.8 12 d275549dex108.htm EX-10.8 EXCLUSIVE CHANNEL COLLABORATION AGREEMENTChannel Collaboration Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionTHIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of February 14, 2013 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and AQUABOUNTY TECHNOLOGIES, INC., a Delaware corporation having its principal place of business at Two Clock Tower Place, Suite 395, Maynard, MA 01754 (“AquaBounty”). Intrexon and AquaBounty may be referred to herein individually as a “Party”, and collectively as the “Parties.”